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Actividad de ceftolozano-tazobactam en 
aislados clínicos de Pseudomonas aeruginosa 
multirresistente y extremadamente resistente 
en un hospital español
RESUMEN
Objetivos. Nuestro objetivo fue evaluar la sensibilidad 
in vitro de ceftolozano-tazobactam en aislados clínicos de 
P. aeruginosa multirresistente (MDR) y extremadamente 
resistente (XDR) desde Febrero de 2016 a Octubre de 2017 
en el Hospital Universitario Miguel Servet, Zaragoza (Es-
paña). 
Material y métodos. Evaluamos la actividad in vitro 
de ceftolozano-tazobactam y otros antibióticos anti-pseu-
domónicos en 12 aislados de P. aeruginosa MDR y en 117 
aislados XDR, no productores de metalo-β-lactamasas. Se 
determinó la concentración mínima inhibitoria (CMI) de 
ceftolozano-tazobactam mediante tiras de difusión en 
gradiente.
Resultados. Entre los 129 aislados MDR/XDR inclui-
dos, 119 (92,2%) fueron sensibles a ceftolozano-tazobac-
tam, y diez (7,8%) presentaron resistencia. La CMI50 fue 
de 2 mg/L, y la CMI90 de 4 mg/L. Ceftolozano-tazobactam 
fue el segundo antibiótico más activo después de colistina, 
superando a amikacina.
Conclusiones. Ceftolozano-tazobactam es una op-
ción de tratamiento válida para infecciones causadas por 
P. aeruginosa MDR y XDR en nuestro entorno.
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ABSTRACT
Objectives. Our objective was to evaluate the in vit-
ro activity of ceftolozane-tazobactam against multidrug 
resistant (MDR) and extensively drug-resistant (XDR) non 
metallo-β-lactamase producing Pseudomonas aerugino-
sa clinical isolates at Hospital Universitario Miguel Servet 
(Zaragoza, Spain) from February 2016 to October 2017.
Material and methods. We evaluated the in vitro 
activity of ceftolozane-tazobactam and other antipseu-
domonal antibiotics against 12 MDR and 117 XDR non 
metallo-β-lactamase producing P. aeruginosa isolates. 
Ceftolozane-tazobactam minimal inhibitory concentra-
tions (MICs) were determined by MIC gradient diffusion 
test strip.
Results. Among the 129 MDR/XDR isolates included, 
119 (92.2%) were susceptible to ceftolozane-tazobactam, 
and ten (7.8%) were resistant. MIC50 was 2 mg/L, and MIC90 
4 mg/L. Ceftolozane-tazobactam was the second most ac-
tive antibiotic after colistin, overtaking amikacin. 
Conclusions. Ceftolozane-tazobactam is a valuable 
treatment option for MDR and XDR P. aeruginosa infec-
tions in our setting.
Keywords: Pseudomonas aeruginosa, multidrug resistance, extensively 
drug resistance, ceftolozane-tazobactam, beta-lactams
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pital Universitario Miguel Servet, Zaragoza (Spain), between 
February 2016 and October 2017. Bacterial identification was 
performed by MALDI-TOF mass spectrometry (Bruker Dal-
tonics) and antimicrobial susceptibility testing by MicroScan 
WalkAway (Beckman Coulter). The following antibiotics were 
routinely tested: ceftazidime, cefepime, piperacillin-tazobac-
tam, aztreonam, imipenem, meropenem, ciprofloxacin, levo-
floxacin, gentamicin, tobramycin, amikacin, and colistin. Cur-
rent EUCAST breakpoints [9] were applied to define resistance/
susceptibility. 
Ceftolozane-tazobactam minimal inhibitory concentra-
tions (MICs) were determined by MIC gradient diffusion test 
strip (Liofilchem). MDR isolates were defined as those non-sus-
INTRODUCTION
Pseudomonas aeruginosa is a ubiquitous non-fermenta-
tive Gram-negative bacterium and one of the leading causes 
of nosocomial infections. A point-prevalence study lead by 
the European Centre for Disease Prevention and Control in 
2011-2012 found that almost 9% of hospital-acquired infec-
tions were caused by P. aeruginosa, whereas a Spanish EPINE 
survey in 2016 identified it as the second cause of nosoco-
mial infections (after Escherichia coli), being present in 10.5% 
of isolates [1]. P. aeruginosa is intrinsically resistant to many 
antibiotics due to the high inducible expression of multidrug 
efflux pumps, low levels of non-specific porins, necessary for 
penetration of hydrophilic antibiotics, and due to the induc-
ible expression of β-lactamases, such as AmpC [2]. P. aerugi-
nosa is also highly capable of developing acquired resistance 
through chromosomal mutations that can lead to overexpres-
sion of AmpC or efflux pumps or to downregulation or loss of 
OprD porin, one of the mechanisms responsible of imipenem 
and meropenem resistance. It can also acquire resistance by 
horizontal gene transfer: plasmid-borne expression of extend-
ed-spectrum β-lactamases (ESBL), aminoglycoside-modifying 
enzymes and 16S rRNA methylases have been described in P. 
aeruginosa [2].
The increasing spread of multidrug-resistant (MDR) and 
extensively-drug resistant (XDR) P. aeruginosa is a growing 
concern worldwide [3]. Recent epidemiological studies re-
ported MDR prevalence in P. aeruginosa of around 15% and 
XDR-prevalence ranging between 2.6% and 9.6% from in- and 
outpatients in North America [4, 5]. In Spain, the prevalence of 
MDR strains is already above 30% [3, 6]. 
Ceftolozane-tazobactam is a combination of a nov-
el cephalosporin with the β-lactamase inhibitor tazobactam, 
approved for the treatment of complicated intra-abdominal 
infections, complicated urinary tract infections, and currently 
under investigation for the treatment of ventilator-associated 
pneumonia [7]. Unlike the previous-generation cephalosporins, 
ceftolozane-tazobactam has demonstrated increased stability 
to AmpC β-lactamases; it is also unaffected by the loss of ex-
pression of OprD porin and by the overexpression of multidrug 
efflux pumps [7]. The activity of ceftolozane is compromised in 
the presence of carbapenemases, such as metallo-β-lactama-
ses (MBL) [7]. Ceftolozane-tazobactam constitutes a valuable 
treatment option for MDR gram-negative pathogens and is 
currently the cephalosporin with the highest activity against 
P. aeruginosa [3, 8].
The objective of the present study was to evaluate the in 
vitro activity of ceftolozane-tazobactam against MDR and XDR 
non MBL producing P. aeruginosa clinical isolates, in order to 
assess its suitability as treatment in infections caused by MDR 
and XDR P. aeruginosa in our setting.
MATERIALS AND METHODS
Samples were obtained from in- and outpatients at Hos-
Characteristics n (%)
Type of sample
Respiratory 59 (45.8)
Urine 51 (39.5)
Surgical wound 9 (7.0)
Blood 2 (1.6%)
Catheter 1 (0.8%)
Others 7 (5.4)
Origin of patient
In-patient 99 (76.8%)
Out-patient 30 (23.2)
MDR 12 (9.3)
XDR 117 (90.7)
Isolates susceptible to: 
Amikacin 101 (78.2)
Gentamicin 31 (24.0)
Tobramycin 54 (41.9)
Ceftazidime 13 (10.1)
Cefepime 14 (10.8)
Piperacillin-tazobactam 8 (6.2)
Ceftolozane-tazobactam 119 (92.2)
Imipenem 16 (12.4)
Meropenem 7 (5.4)
Aztreonam 0 (0)
Ciprofloxacin 10 (7.0)
Levofloxacin 5 (3.9)
Colistin 128 (99.2)
Isolates only susceptible to colistin and amikacin 49 (38)
Isolates only susceptible to colistin 13 (10.1)
Table 1  Characteristics of the 129 MDR/XDR  
P. aeruginosa isolates.
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and tobramycin (41.9%). A few isolates were susceptible to 
imipenem (12.4%), meropenem (5.4%), ceftazidime (10.1%), 
cefepime (10.8%) and piperacillin-tazobactam (6.2%). Only 34 
(26.3%) isolates were susceptible to all the β-lactams tested. 
Thirteen (10.1%) isolates were only susceptible to colistin, and 
49 (38%) were only susceptible to colistin and amikacin.
When susceptibility to ceftolozane-tazobactam was ana-
lyzed, 119 isolates (92.2%) were susceptible and 10 (7.8%) iso-
lates showed MIC above the susceptibility breakpoint (4 mg/L); 
MIC50 was 2 mg/L, and MIC90 was 4 mg/L (figure 1). Among the 
10 resistant isolates, five were susceptible to amikacin, and all 
were susceptible to colistin. Nine isolates were non-susceptible 
to the other β-lactams tested, and only one isolate was sus-
ceptible to imipenem and meropenem. Seven of the ten resist-
ant isolates came from respiratory specimens. 
DISCUSSION 
Although β-lactams are the mainstream therapy for P. 
aeruginosa infections, resistances to these drugs are increas-
ingly common [1,3,4,5]. Thus, oprD porin mutation-mediated 
suppression causes resistance to carbapenems; overexpression 
of β-lactamase AmpC inactivates penicillins, cephalosporins 
and monobactams, whereas efflux pump up-regulation causes 
resistance to various β-lactams, fluoroquinolones and amino-
glycosides. Plasmid-encoded ESBLs and MBLs are emergent 
and worrisome mechanisms of resistance in P. aeruginosa [1]. 
The combination of the fifth-generation cephalospor-
in ceftolozane, which is less affected by loss of OprD, over-
expression of efflux pumps or AmpC than other available 
β-lactams, joined to tazobactam, which inhibits a wide variety 
ceptible to ≥ 1 agent in at least 3 antibiotic classes; XDR iso-
lates were defined as those only susceptible to ≥ 1 agent in 
maximum 2 antibiotic classes [10]. MBL producing isolates 
were excluded from the analysis since ceftolozane-tazobac-
tam is not active against them. MBL production was screened 
by phenotypic methods: combined disk test with imipen-
em 10 µg (Oxoid) and imipenem 10 µg with 750 µg of EDTA 
(Sigma-Aldrich) in-house added and by Neo-Rapid CARB Kit 
(Rosco); and confirmed by real-time PCR (Check Direct CPE Kit 
Check-Points Health B.V.).
RESULTS
During the period studied, a total of 1,421 P. aerugino-
sa non-duplicate isolates were obtained; of these, 141 (9.9%) 
were defined as MDR and 316 (22.2%) as XDR. A total of 68 
(4.7%) isolates were MBL producing. 
In a total of 129 MDR/XDR P. aeruginosa non-duplicate 
isolates (one isolate per patient) and non-MBL producing 
ceftolozane-tazobactam could be tested and were included in 
the study. Of the 129 isolates, 12 (9.3%) were defined as MDR 
and 117 (90.7%) as XDR. One hundred-and-eight (83.7%) pa-
tients were male, mean age (SD) was 63.9 (18.0) years; most 
were in-patients (76.8%). The majority of isolates were from 
respiratory samples (45.8%) and urine samples (39.5%). The 
rates of susceptibility to the antibiotics included in the pan-
el and other characteristics are summarized in table 1. Most 
isolates were classified as XDR, with a median of two active 
antibiotics out of 12 tested (range: 0-8). All except one isolate 
were susceptible to colistin. Other antibiotics more frequent-
ly active against P. aeruginosa isolates were amikacin (78.2%) 
Figure 1  Distribution of ceftolozane-tazobactam minimal inhibitory concentrations 
(MIC) among the 129 P. aeruginosa isolates.
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15. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, 
of beta-lactamases (but not AmpC or MBLs), covers most of 
the pathogens causing β-lactam resistance [7]. Indeed, in the 
present study, only 7.8% of MRD/XDR non-MBL isolates were 
resistant to ceftolozane-tazobactam, whereas almost 75% of 
them were non-susceptible to the rest of the tested β-lactams. 
Two previous studies reported similar rates (from 4.8% to 7%) 
of non-MBL mediated resistance to ceftolozane-tazobactam in 
MDR and XDR P. aeruginosa [11,12].
In our study, we did not further explore the mechanisms 
of such resistance. When Moya et al. explored the mecha-
nisms of pan-β-lactam resistance in P. aeruginosa (including 
ceftolozane), they found that all pan-resistant isolates lacked 
OprD, overexpressed AmpC and efflux pumps, and 5 out of 6 
isolates had modifications in penicillin-binding protein (PBP) 
profiles [13]. An epidemiological study on a collection of 150 
XDR isolates from Spanish hospitals reported an overall rate of 
non-susceptibility to ceftolozane-tazobactam of 31%, mediat-
ed by horizontally acquired carbapenamases, although poten-
tially relevant PBP3 mutations were also detected [14]. Other 
studies identified AmpC overexpression and chromosomal mu-
tations as potential mechanism of resistance to ceftolozane/
tazobactam [15-17]. In our study, the ceftolozane-tazobactam 
MIC for non-MBL producing isolates ranged between 8 and 16 
mg/L, which is only 2-4 fold higher that the breakpoint. It is 
reasonable to suggest that a massive overexpression of AmpC 
and/or the mutations, such as target modification, could lead 
to the observed non-MBL-mediated resistance. 
Nonetheless, the activity of ceftolozane-tazobactam 
against the tested MDR and XDR isolates was high (92.2%) 
and was only surpassed by colistin. We conclude that ceftolo-
zane-tazobactam is a valuable treatment option for compli-
cated infections caused by MDR and XDR non-MBL producing 
P. aeruginosa isolates in our setting.
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